evipedia.aidev
← Back

Melatonin for Health & Longevity

Evidence Review created on 08/26/2026 using AI4L / Grok 4

Also known as: N-Acetyl-5-methoxytryptamine, 5-Methoxy-N-acetyltryptamine, Circadin

Motivation

Melatonin is a hormone the pineal gland in the brain releases after dusk. It tells tissues that night has arrived so sleep can start at a biologically appropriate time. People seeking better long-term health often consider an oral melatonin supplement because pineal output falls with age, because travel and evening light scramble that signal, and because laboratory work has painted melatonin as an antioxidant inside cells.

Nightly use is now one of the most common non-prescription sleep practices in North America, while in much of Europe the same molecule is a prescription medicine for insomnia in later life. Popular books in the 1990s framed melatonin as a longevity hormone. Later human trials concentrated on jet lag and falling asleep.

This review examines the human evidence that oral melatonin changes sleep timing, sleep quality, blood pressure, and other longevity-relevant outcomes, and it weighs those findings against adverse events, product-quality problems, hormone and drug interactions, and the still-open question of long-term heart effects.

Benefits - Risks - Protocol - Conclusion

High-level overviews of melatonin as a sleep-timing hormone, a supplement with erratic labeling, and a longevity candidate.

Chris Kresser’s site discusses evening light suppressing melatonin but has no dedicated supplementation overview. No second item was taken from any one expert or organization.

Grokipedia

  • Melatonin

    A structured encyclopedia page covering pineal and mitochondrial melatonin, receptor and non-receptor actions, sleep and non-sleep uses, and product-quality problems.

Examine

  • Melatonin

    Independent evidence grades across sleep, blood pressure, migraine, reflux, and other outcomes, plus liver-enzyme interaction and product-quality notes.

ConsumerLab

  • Melatonin Supplements Review

    Independent product assays and a public summary on dose, timed-release forms, grogginess, and interactions; ConsumerLab sells memberships to the full rankings.

Systematic Reviews

PubMed systematic reviews and meta-analyses that quantify melatonin’s sleep-timing effects, nocturnal blood pressure, and high-dose safety.

Mechanism of Action

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone the pineal gland releases after dusk. Light via the eyes keeps pineal synthesis off; darkness lifts that brake. Circulating melatonin binds two G-protein-coupled receptors, MT1 and MT2 (melatonin receptor types 1 and 2), densely expressed in the suprachiasmatic nucleus (SCN, the brain’s master clock). MT1 tends to quiet SCN firing and open a sleep window; MT2 shifts clock phase. That is a timing signal, not a typical sedative-hypnotic.

Immediate-release oral melatonin typically peaks in plasma in about 50 minutes, has an elimination half-life near 45 minutes, and oral bioavailability of roughly 9–33% (often near 15%) after heavy first-pass extraction. Hepatic cytochrome P450 1A2 (CYP1A2, a liver enzyme that also metabolizes caffeine, fluvoxamine, and many other drugs) is the main route, with smaller roles for CYP2C19 (another liver enzyme that metabolizes several drugs, including some acid-suppressing medicines) and CYP1A1 (a related enzyme more active outside the liver); 6-sulfatoxymelatonin is the urinary metabolite.

A second account holds that most body melatonin is made inside mitochondria, scavenging reactive oxygen species without MT1/MT2, and that gut cells make large amounts. Those receptor-independent antioxidant and immune effects are the usual rationale for 10–20 mg oncology-style doses, which drive plasma levels far above the nocturnal pineal peak of about 60–100 pg/mL. Fluvoxamine, oral contraceptives, caffeine, smoking, age, and feeding status all change exposure.

Historical Context & Evolution

Aaron Lerner isolated melatonin from bovine pineal tissue in 1958 while seeking a skin-lightening factor; the name records its action on amphibian melanophores. Josephine Arendt and colleagues in the 1970s and 1980s established it as the chemical darkness signal and ran the first jet-lag and shift-work trials. The 1994 Dietary Supplement Health and Education Act then allowed U.S. over-the-counter sale without a prescription-drug indication.

Walter Pierpaoli and William Regelson’s 1995 book The Melatonin Miracle, plus mouse pineal-graft and feeding studies, framed nightly melatonin as a longevity practice. Those animal lifespan findings were never confirmed as human outcome trials, and they are not dismissed here as closed. Life Extension began selling melatonin in 1992. The European Medicines Agency approved 2 mg prolonged-release melatonin (Circadin, Neurim Pharmaceuticals) in 2007 for primary insomnia in adults aged 55 years and older, as replacement for an age-related nocturnal decline rather than as a sedative. Russel Reiter’s group later argued that mitochondrial melatonin, not pineal output, underpins antioxidant and anti-cancer claims. Product assays from 2017 onward showed large deviations from labeled content. A 2025 American Heart Association meeting abstract linked long-term prescription melatonin to heart failure; that observational signal has not been tested in a randomized trial.

Expected Benefits

High 🟩 🟩 🟩

Jet Lag After Eastward Travel

Crossing several time zones leaves the master clock behind local night. Evening melatonin at the destination bedtime supplies a dusk signal, most clearly after eastward flights of five or more zones. A Cochrane review of randomized airline and military trials found consistent jet-lag reductions; 0.5 mg and 5 mg were similar for symptoms, with 5 mg faster sleep. Wrong-time (morning) doses can delay adaptation.

Magnitude: Number needed to treat of 2 for jet lag after five or more time zones; 0.5–5 mg similar for symptoms.

Sleep Onset, Especially Delayed Sleep-Wake Phase ⚠️ Conflicted

Pooled randomized trials show melatonin shortens time to fall asleep. The effect is large in delayed sleep-wake phase disorder (sleep timing hours later than desired) and modest in ordinary insomnia. One meta-analysis reported about 7 minutes overall and another nearly 40 minutes in delayed-phase samples. The American Academy of Sleep Medicine, whose members bill for behavioral insomnia care, sleep studies, and prescription hypnotics, endorses melatonin for circadian disorders but not for chronic insomnia. Net reading: meaningful for delayed clocks, small for typical insomnia.

Magnitude: Sleep onset about 7 minutes faster overall and about 39 minutes faster in delayed sleep-wake phase disorder.

Subjective Sleep Quality

Quality on the Pittsburgh Sleep Quality Index (PSQI, a 0–21 questionnaire; lower is better) improved by about 1.2 points in a 23-trial meta-analysis, with larger effects in respiratory and metabolic disease than in primary mental or neurodegenerative illness. Total sleep time gains are on the order of 8 minutes. These are human clinical scores, but most trials are short and doses vary widely.

Magnitude: PSQI about 1.24 points lower; total sleep about 8 minutes longer.

Nocturnal Blood Pressure With Controlled-Release Forms

Controlled-release evening melatonin has lowered nocturnal systolic and diastolic pressure in more than one randomized trial, consistent with nighttime receptor effects on vascular tone. Immediate-release forms have not shown the same nocturnal effect. A hypertension-focused meta-analysis found an asleep systolic drop of about 3.6 mm Hg for controlled-release product that did not reach statistical significance; an earlier controlled-release subgroup reported −6.1/−3.5 mm Hg. People already on blood-pressure drugs can see additive lowering.

Magnitude: Controlled-release nocturnal systolic pressure about 3.6 to 6.1 mm Hg lower; immediate-release nocturnal effect consistent with no change.

Medium 🟩 🟩

Migraine Day Reduction

In a three-arm randomized trial, melatonin 3 mg reduced monthly migraine days by 2.7 versus 1.1 on placebo, matching amitriptyline 25 mg with fewer adverse events. A systematic review of mixed randomized and observational work called the evidence promising but still limited by study quality. This is a human headache-frequency endpoint from a single strong trial, hence Medium.

Magnitude: About 2.7 fewer migraine days per month versus 1.1 on placebo (3 mg for 12 weeks).

Low 🟩

Heartburn in Gastroesophageal Reflux

Small trials report less heartburn with evening melatonin, sometimes in multi-ingredient formulas, including one omeprazole comparison and a melatonin-versus-omeprazole series. Samples are tiny, and a nutraceutical reflux meta-analysis did not isolate a robust melatonin effect. Human symptom data exist but are confounded.

Magnitude: Complete symptom regression in one multi-ingredient trial versus 66% on omeprazole; not isolated to melatonin alone.

Solid-Tumor One-Year Survival (Add-On) ⚠️ Conflicted

Two meta-analyses of randomized solid-tumor trials, mostly 20 mg nightly, reported higher one-year survival (Seely, Wang). Nearly all positive trials come from one Italian group; independent replication is sparse. Net reading: a large published effect unconfirmed outside that trial network.

Magnitude: Pooled relative risk (event rate versus control) for one-year mortality 0.63; one-year survival 52% versus 28% in the smaller 20 mg meta-analysis.

Speculative 🟨

Human Lifespan or Healthspan Extension

Pineal-graft and high-dose mouse studies, plus mitochondrial antioxidant biochemistry, motivate longevity use. No controlled human trial has measured lifespan or a validated aging-clock outcome. Basis is animal and mechanistic only.

Mitochondrial Antioxidant Replacement

Oral melatonin reaches mitochondria in experimental models and can scavenge radicals in vitro. No validated human mitochondrial outcome has been shown after usual oral doses. Basis is laboratory only.

Benefit-Modifying Factors

  • Melatonin receptor 1B gene (MTNR1B) variants: The rs10830963 G allele, which affects pancreatic insulin release, raises fasting glucose; evening melatonin can worsen glycemic responses in carriers.
  • Baseline nocturnal melatonin: Older adults and people with pineal calcification (age-related hardening of the pineal gland) or bright evening light have lower peaks; replacement-range doses may shift sleep timing more than in high secretors.
  • Sex: Endogenous nighttime levels are often slightly higher in women; menopausal sleep disruption is a common context, but sex-specific dose-response data remain sparse.
  • Delayed clocks versus insomnia: Circadian delay yields larger sleep-onset gains than psychophysiologic insomnia, where hyperarousal, not a missing dusk signal, dominates.
  • Age: Nocturnal pineal output falls after midlife; prolonged-release 2 mg was studied mainly in adults 55 years and older with primary insomnia.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Next-Day Somnolence, Headache, Dizziness, and Vivid Dreams

Melatonin lowers alertness after a dose and commonly causes headache, dizziness, nausea, and vivid dreams. Next-morning grogginess is the adverse event that most often appears in trials, especially at higher milligram amounts and with controlled-release products. A meta-analysis of doses of 10 mg or more found more adverse events such as drowsiness, headache, and dizziness (rate ratio 1.40, or 40% more events than placebo) without a clear rise in serious events. Symptoms are usually mild and reverse on stopping or dose reduction.

Magnitude: Adverse-event rate ratio 1.40 at ≥10 mg; drowsiness, headache, and dizziness drove the excess.

Medium 🟥 🟥

No risk reaches Medium: the replicated product-content assays are indirect exposure data rather than a clinical endpoint, and the remaining human harms are either trial-replicated (High) or conflicting or uncontrolled (Low).

Low 🟥

Delivered Dose That Does Not Match the Label

Erland and Saxena found 31 retail products ranging from 83% below to 478% above the label, some with serotonin. Cohen and colleagues found 3 of 25 gummies within 10% of labeled melatonin; one had cannabidiol and no melatonin. This is replicated exposure error, not a trial of organ damage.

Magnitude: Label error from −83% to +478%; only 12% of tested gummies within ±10% of claim.

Incident Heart Failure in Insomnia Records ⚠️ Conflicted

A 2025 meeting analysis of insomnia records found more heart failure and death after a year of listed melatonin use (newsroom summary). It is observational and unpublished as a full paper; a blood-pressure meta-analysis points the other way. Net reading: hypothesis-generating, not proven cardiac harm.

Magnitude: Incident heart failure 4.6% versus 2.7% over 5 years (hazard ratio (relative event rate versus comparators) of 1.89) in matched insomnia records.

Reproductive-Hormone Suppression ⚠️ Conflicted

Melatonin can suppress gonadotropin-releasing hormone (GnRH, the brain’s puberty and sex-hormone signal) in seasonal breeders. In healthy men, 6 mg nightly for one month did not change testosterone. Net reading: no gonadal shutdown in adult men at moderate dose; adolescents and high doses remain less tested.

Magnitude: No change in luteinizing hormone, follicle-stimulating hormone, or testosterone after 6 mg nightly for 1 month in healthy men.

Fracture After Repeated Prescriptions ⚠️ Conflicted

A UK primary-care cohort found more fractures after three or more prescriptions (adjusted hazard ratio 1.44). A later self-controlled analysis saw the excess before the first fill, implicating insomnia itself. Net reading: an observational signal in older adults, not shown to be causal.

Magnitude: Adjusted hazard ratio 1.44 versus matched unexposed adults; elevated only after three or more prescriptions.

Speculative 🟨

Lasting Pineal Shutdown After Stopping

A common claim is that nightly supplements shut down the pineal gland. Controlled human work has not shown lasting failure of endogenous production after stopping usual doses. Basis is anecdotal and mechanistic only.

Risk-Modifying Factors

  • CYP1A2 activity: Slow CYP1A2 metabolizers and people taking fluvoxamine or oral contraceptives can see several-fold higher melatonin exposure and next-day sedation.
  • Baseline blood pressure: Controlled-release melatonin can lower nocturnal pressure; people on antihypertensives may see additive drops or, with nifedipine, reduced drug effect.
  • Sex and reproduction: High-dose concerns about gonadotropins are stronger in adolescents; adult men given 6 mg nightly for a month showed no pituitary-gonadal change.
  • Autoimmune and seizure history: Isolated reports of immunostimulation and seizure worsening make preexisting autoimmunity or epilepsy relevant modifiers.
  • Age: Next-day grogginess, falls, fracture after repeated prescriptions, and the 2025 heart-failure observational signal concentrate in older adults with insomnia and cardiometabolic disease.

Key Interactions & Contraindications

  • CYP1A2 inhibitors (fluvoxamine, oral contraceptives, ciprofloxacin, grapefruit juice): Caution. Can multiply melatonin exposure and next-day sedation; a lower milligram amount or avoidance of fluvoxamine co-use is the usual mitigation.
  • CYP1A2 inducers (smoking, carbamazepine, rifampin): Caution. Faster clearance can blunt sleep-timing effects; timing and dose may need reassessment if induction starts or stops.
  • Sedating prescription drugs (benzodiazepines, zolpidem, trazodone, opioids): Caution. Additive impairment of driving and morning function; separate from other evening sedatives when possible.
  • Over-the-counter sedatives (diphenhydramine, doxylamine, alcohol): Caution. Same additive sedation as prescription hypnotics; alcohol additionally fragments sleep architecture.
  • Anticoagulants (warfarin): Monitor. Case reports of a higher international normalized ratio (INR, a clotting-time score); more frequent INR checks if melatonin is added.
  • Antihypertensives (amlodipine, lisinopril) and nifedipine: Monitor or caution. Controlled-release melatonin can add nocturnal pressure drop; nifedipine effect may fall.
  • Glucose-lowering drugs and evening carbohydrate loads: Monitor. MTNR1B variant carriers can see higher fasting glucose after evening melatonin.
  • Immunosuppressants (tacrolimus, cyclosporine) and immunostimulants: Caution. Theoretical immune stimulation; transplant recipients are often advised to avoid unsupervised use.
  • Additive sleep supplements (magnesium glycinate, L-Theanine, glycine, valerian): Caution. Extra evening sedation and vivid dreams without a melatonin-sparing trial basis.
  • Caffeine: Monitor. Shares CYP1A2; late caffeine both delays sleep and can raise melatonin levels.

Populations who should avoid Melatonin:

  • Pregnancy and lactation (supplemental exposure not established as safe)
  • Uncontrolled epilepsy
  • Child-Pugh class C cirrhosis (impaired CYP1A2 clearance)
  • Unstable warfarin anticoagulation without INR monitoring
  • Autoimmune disease under active immunosuppression, pending specialist review
  • Children and adolescents outside specialist sleep care (pubertal-axis uncertainty)
  • Anyone who must drive or operate machinery the same night until next-day alertness is known

Risk Mitigation Strategies

  • Lowest effective milligram amount: Starting at 0.3–1 mg limits next-day somnolence and shrinks the harm of label overage.
  • Third-party assayed lots: USP, NSF, or equivalent testing reduces the −83% to +478% content swings documented in retail assays.
  • Evening-only clock timing: Dosing at destination or target bedtime, never local morning after eastward travel, avoids delayed adaptation and daytime sleepiness.
  • Sedative inventory: Holding other evening hypnotics, first-generation antihistamines, and alcohol on melatonin nights cuts additive impairment.
  • INR and blood-pressure checks: Repeat INR after starting if on warfarin and nocturnal or morning pressure if on antihypertensives, to catch bleeding risk or additive nighttime hypotension.
  • Fall precautions after age 45: Residual grogginess can raise fracture risk; keep night lighting and reassess standing balance in the first weeks.
  • Glucose watch in MTNR1B carriers: Fasting glucose after 1–4 weeks detects a melatonin-related glycemic rise.
  • As-needed rather than automatic nightly use: Reserving melatonin for travel and delayed nights limits cumulative exposure while long-term cardiac data remain observational.

Therapeutic Protocol

  • Timing: Evening only, typically 30–180 minutes before desired sleep; dose-response work favors about 3 hours before the sleep episode for onset.
  • Immediate-release amount: Many sleep trials use 0.5–5 mg; physiologic-range 0.3 mg can phase-shift. Higher milligrams are not consistently better for sleep.
  • Prolonged-release: Circadin 2 mg 1–2 hours before bed after food, studied up to 13 weeks in adults 55 years and older with primary insomnia.
  • Half-life and splitting: Immediate-release half-life is about 45 minutes, so a single evening dose is usual; split daytime doses oppose nocturnal timing.
  • Jet lag: 0.5–5 mg at destination bedtime after eastward flights of five or more zones, for several nights.
  • Genetics: MTNR1B rs10830963 G-allele carriers can have worse fasting glucose after evening melatonin; glycemic monitoring informs timing.
  • Sex: Adult men at 6 mg for a month lacked gonadal change; pregnancy and lactation remain avoidance settings.
  • Age: Lower pineal peaks after midlife; start at 0.3–1 mg because residual morning sedation is more costly with age.
  • Baseline light and melatonin: Bright evening light suppresses pineal output; supplements do not replace darkness and morning daylight.
  • Conditions: Delayed sleep-wake phase and jet lag respond more than chronic insomnia driven by hyperarousal.
  • Competing clinics: Huberman and Walker favor 0.1–0.3 mg or none except travel; Circadin programs use 2 mg prolonged-release; some integrative oncology clinics use 20 mg with chemotherapy.

Discontinuation & Cycling

  • Intended duration: Circadian uses are short courses; nightly year-plus use is common but lacks long-term outcome trials.
  • Withdrawal: Stopping usual doses does not produce a recognized withdrawal syndrome comparable to benzodiazepines.
  • Taper: Not required for physiologic or low milligram doses; stepping down from 10 mg may ease morning grogginess.
  • Cycling: No evidence that scheduled off-weeks preserve receptor sensitivity; some practitioners reserve it for travel and delayed nights.

Sourcing and Quality

  • Synthetic versus animal extract: Pharmaceutical-grade synthetic melatonin avoids pineal-extract contaminants that older glandular products carried.
  • Third-party testing: USP, NSF, or equivalent lot assays matter because labeled milligrams are often wrong.
  • Labeled milligrams: 0.3–1 mg scored tablets keep delivered dose low even if manufacturing overage exists.
  • Form: Immediate-release for phase-shifting; prolonged-release when nocturnal blood pressure or middle-of-night waking is the target.
  • Brands: Circadin is the regulated European medicine; U.S. examples with testing programs include Pure Encapsulations, Thorne, and Life Extension (which also sells the products it writes about).
  • Gummies: Highest label-error and contaminant rates in published assays; capsules and tablets assay more cleanly.

Practical Considerations

  • Time to effect: Sleep-onset change can appear the first night; jet-lag benefit over 2–4 destination nights; migraine prevention over about 12 weeks.
  • Common pitfalls: Taking it at local morning after eastward travel; combining multiple 10 mg gummy products; using it instead of darkness and a fixed wake time.
  • Regulatory status: U.S. dietary supplement, not approved by the Food and Drug Administration (FDA) for insomnia; EU prescription prolonged-release for primary insomnia at age 55 and over.
  • Cost: Generic 1–3 mg is inexpensive; Circadin costs more. Payers that reimburse Circadin or billed behavioral insomnia therapy have a structural incentive to favor those over unregulated generics, a possible bias in guidelines and funding.

Interaction with Foundational Habits

  • Sleep: Direct and, when timed to dusk, potentiating for sleep onset; blunting if taken in local morning. Mechanism is MT1/MT2 signaling in the SCN. Darkness, a cool room, and a stable wake time still set pineal output; morning daylight remains the stronger clock setter.
  • Nutrition: Indirect via CYP1A2 and tryptophan. Late caffeine can both delay sleep and raise melatonin levels. High-tryptophan foods and tart cherry supply trivial milligrams versus tablets. Large meals near the dose slow absorption.
  • Exercise: Indirect. Evening vigorous training can delay sleep; melatonin is sometimes used after late competition. Morning exercise reinforces the clock and does not require a dose change.
  • Stress management: Indirect, often blunting the apparent benefit. Hyperarousal insomnia responds better to behavioral therapy than to a dusk signal. Melatonin does not replace wind-down practices that lower cognitive arousal.

Monitoring Protocol & Defining Success

Before the first evening dose, a one- to two-week sleep diary (bedtime, sleep onset, awakenings, rise time, next-day alertness) plus a Pittsburgh Sleep Quality Index score establishes the individual’s baseline. People with hypertension or suspected non-dipping (nighttime pressure that falls less than 10% below daytime) benefit from 24-hour ambulatory blood pressure; those with diabetes or a known melatonin-receptor gene variant benefit from a fasting glucose. Ongoing checks at one week, four weeks, and then every three to six months ask whether sleep onset has moved earlier without morning grogginess, and whether blood pressure or glucose has shifted. Urinary 6-sulfatoxymelatonin reflects intake while a person is dosing and does not measure remaining pineal output. Success is a stable, earlier sleep onset, preserved next-day function, and no new nocturnal hypotension or fasting-glucose rise—not a higher milligram count.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Sleep onset latency <20 minutes Tracks the sleep-timing effect Sleep diary or actigraphy; conventional insomnia often >30 minutes
PSQI <5 Composite sleep quality Self-report; conventional poor sleep is ≥5
Morning residual sleepiness (0–10) No established target; track return to personal baseline Captures next-day somnolence Rate on waking; no universal cutoff
Nocturnal systolic dip 10–20% below daytime Controlled-release melatonin can deepen the dip 24-hour ambulatory monitor; conventional non-dipping is <10%
Fasting glucose 70–90 mg/dL (3.9–5.0 mmol/L) Evening melatonin can raise fasting glucose in MTNR1B carriers Morning fast; conventional reference is typically <100 mg/dL

Qualitative markers:

  • First-night versus week-four ease of falling asleep at the intended hour
  • Morning grogginess, vivid dreams, and next-day driving comfort
  • Headache or dusk-onset temperature drop that feels excessive
  • Stable mood; new low mood is a reported, uncommon adverse effect

Emerging Research

  • Alzheimer biomarkers: NCT03954899 is recruiting about 230 adults aged 56–85 for 5 mg versus placebo over 9 months, with cognition and blood Alzheimer markers as endpoints.
  • Cardiometabolic events: NCT04631341 lists a 10,000-person Chinese randomized prevention study of 5 mg nightly for cardiovascular and cancer incidence; status remains not yet recruiting despite a 2020 posting.
  • Heart-failure signal: Nnadi et al. presented an insomnia-records analysis at the American Heart Association (AHA) 2025 meeting, described in an AHA newsroom summary, showing higher heart-failure rates; if replicated in trials, it would weaken the case built from small blood-pressure studies.
  • Antibiotic kidney injury: NCT05084196 is a recruiting phase 3 trial of 5 mg versus placebo to prevent vancomycin-associated acute kidney injury (n=300).

Conclusion

Melatonin is the darkness hormone of the pineal gland and a widely used evening oral supplement. The strongest human signal is better alignment of sleep timing: jet lag after eastward flights and delayed sleep onset, especially when the body clock itself runs late. Gains in ordinary insomnia are real in pooled trials and small. Controlled-release forms can lower nighttime blood pressure in people with hypertension. Migraine-day reductions appear in at least one well-run comparison. Claims that nightly melatonin extends life or improves cancer survival rest on weaker or conflicted human data.

Common adverse events are next-day sleepiness, headache, dizziness, and vivid dreams. Over-the-counter products often fail to match the labeled dose. Observational records show more fractures after repeated prescriptions in older adults and more heart failure diagnoses after year-long insomnia use; those findings are unpublished or uncontrolled and sit beside randomized data showing modest blood-pressure lowering. Adult men given a moderate nightly dose for a month did not show reproductive-hormone shutdown. Supplement makers and the prescription prolonged-release manufacturer have a financial interest in expanding use; sleep-medicine groups that favor behavioral therapy or prescription sleep medications have a different incentive structure. For a health-optimizing adult, melatonin is a timing tool that does not linger in the body, with a modest sleep-onset effect and unresolved long-term heart questions—not a general longevity drug.

Top - Benefits - Risks - Protocol